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changes in the expression of cytokines and growth factors have implications in the malignant transformation of many cancers 
may be used as additional diagnostic markers in the sera of patients because of their excessive production by the tumor cells. This 
could be of great value since there are currently no reliable markers to predict either tumor development or relapse. Interleukin-8 
(IL-8), a chemokine (C-X-C motif) ligand 8 (CXCL8), is now reported to play an important role in cancer invasion, angiogenesis 
and metastasis. Recent studies have shown an increased concentration of IL-8 in patients with LSCC and a positive association 
and cancer progression-free survival. The investigation of the mechanisms of origin, invasion, and metastasis of the cancer is 
could have a role as a screening test and as a support of the clinical decisions for appropriate therapy and postoperative care 
in individual patients. Biomed Rev 2018; 29: 47-55
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INTRODUCTION
Laryngeal squamous cell cancer (LSCC) is the second most 
common neoplasm of the upper aerodigestive tract after cancer 
of the oral cavity (1). Over the past two decades, even though 
surgical techniques, chemotherapy and radiation therapy, the 
In 2016, an estimated 13,430 new cases of laryngeal cancer 
have been diagnosed, with approximately 3620 patients 
dying from the disease. Laryngeal squamous cell cancer 
occurs more commonly in men than in women (5.8 cases per 
100.000 vs 1.2 per 100.000, respectively). In addition, there 
are racial disparities observed in laryngeal cancer, with African 
Americans presenting at a younger age and having a higher 
incidence and mortality compared with Caucasians (2). 
 Several risk factors have been implicated in the pathogenesis 
alcohol consumption (4). Tobacco use has been shown to have 
a linear association with the development of laryngeal cancer, 
with a risk for smokers that is 10 to 15 times higher than the 
risk for nonsmokers, and the heaviest smokers have as much 
as a 30 times greater risk. Research has also demonstrated a 
linear relationship between the amount of alcohol consumed 
and the risk of laryngeal cancer. In a study that examined the 
role of alcohol and tobacco in laryngeal cancer, the multivariate 
as > 8 drinks per day) and 9.38 for nondrinking smokers (5-
11). It has also been shown that alcohol and tobacco have a 
multiplicative effect on the risk of laryngeal cancer. 
 Exposure to other environmental factors is thought to 
potentially increase the risk of LSCC, such as asbestos, 
polycyclic aromatic hydrocarbons, and textile dust (12). 
Dietary factors have also been noted, with red meat increasing 
the risk of laryngeal cancer, while a diet varied in fruit and 
vegetables potentially has a protective effect. The role that both 
disease process is still controversial and under investigation. 
 Although the human papillomavirus (HPV) is a proven 
driver of the majority cancers of the oropharynx, it was 
initially thought that the virus did not play a role in laryngeal 
cancer (13-18). However, new research demonstrates the 
presence of HPV and/or the surrogate marker p16 (cyclin-
dependent kinase inhibitor 2A/multiple tumor suppressor 1) 
in a minority of laryngeal tumors, although the biologic and 
that the prevalence of HPV ranges from 20% to 30% in 
laryngeal cancer; however, this percentage varies widely 
between studies and depends on the detection method used. 
More work is needed to determine the clinical relevance of 
HPV/p16-positive status in laryngeal cancer, as this remains 
controversial (13-21).
 Approximately 60% of patients present with advanced 
(stage III or IV) disease at diagnosis. Unfortunately, laryngeal 
cancer is one of the few oncologic diseases in which the 
5-year survival rate has decreased over the past 40 years, 
from 66% to 63%, although the overall incidence is declining. 
This highlights the need for further research and innovation 
rate are the lack of screening methods (clinical examination 
remains the single solution to early detection) and the late 
presentation of patients to the specialist as a result of little 
worrying symptoms (hoarseness). The lack of suspicion of 
second consultation among patients who were not diagnosed 
with cancer initially (1, 25).
CYTOKINES IN HEAD AND NECK CANCER
It has been reported that changes in the expression of 
cytokines and growth factors may have implications in the 
malignant transformation of many cancers including head 
and neck squamous cell carcinoma (HNSCC) and, more 
recently, LSCC (2, 26). Cytokines are a group of soluble, 
low-molecular-weight proteins that mediate immune and 
groups: T-helper 1 (Th1), T-helper 2 (Th2) and T-helper 17 
(Th17), as determined by their biological properties (27). 
Th1 cytokines stimulate cellular immune responses, while 
Th2 cytokines predominantly regulate humoral responses. 
and plays several roles in autoimmunity (27). Cytokines are 
(28). As for nerve growth factor (NGF), several studies led 
distribution pattern within the tissues and its implication in 
induction as well as progression of carcinogenesis. However, 
other recent studies have shown that NGF may have direct 
clinical relevance in certain tumor cell prevention (29-32).  
 Involvement of cytokines in the pathogenesis of cancer, 
and especially HNSCC, has been investigated in a number 
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of recent studies (33-36). These studies have categorized 
cytokines as (a) factors that affect tumor growth, (b) factors 
that can be used as prognostic markers and (c) those that are 
possible immunotherapeutic targets (37). Although the main 
source of cytokines are immune cells, many tumor cells have 
been shown to make autocrine mediators to support their own 
growth thus evading the immune response (38); they include 
HNSCC that produce IL-4, IL-6, IL-8, IL-10, granulocyte 
macrophage-colony-stimulating factor (GM-CSF), VEGF, 
factor (bFGF). 
 It has been hypothesized that some of these cytokines may 
be used as additional diagnostic markers in the sera of patients 
because of their excessive production by the tumor cells (39). 
This could be of great value since there are currently no reliable 
markers to predict either tumor development or relapse in 
treated HNSCC patients. Recent studies have demonstrated 
that HNSCC is associated to a decrease in Th1 and an increase 
in Th2 cytokine levels, which is thought to be used as a 
mechanism to evade anti-tumor immune response. In fact, this 
shift towards the Th2 cytokine response is a common event 
in HNSCC and many other solid tumors, such as colorectal 
cancer, renal cell carcinoma, prostate cancer, and melanoma. 
Therefore, current studies in search of immunotherapeutic 
approaches to cancer aim to shift the balance in favor of Th1 
response. 
NEUTROPHIL-TO-LYMPHOCYTE RATIO 
An increased neutrophil-to-lymphocyte ratio (NLR) is 
associated with poorer prognostic outcomes in numerous 
types of cancer, including HNSCC (40-43). However, a small 
number of studies have demonstrated the prognostic role of 
NLR in patients with laryngeal cancer (44). The association 
between NLR and survival outcomes in 654 patients with 
LSCC was evaluated (45) and the authors reported that 
blood and biochemical parameters, including NLR, platelet-
to-lymphocyte ratio and albumin-to-globulin ratio were 
associated with clinical characteristics of the patients, with the 
exception of histologic grade. Survival analysis demonstrated 
that NLR at cutoff values subdivided patients into different 
survival outcomes; subsequent to adjustments for age and other 
prognostic factor for overall survival and progression-free 
survival. Increased levels of cytokines, including IL-6 and 
IL-8 in tumor tissues were associated with NLR values. 
In summary, pre-treatment NLR was associated with the 
prognostic outcomes for patients with laryngeal cancer and 
may assist to establish prognostic factors for these patients.
INTERLEUKIN-8 
chemoattractant, is now reported to play an important role in 
cancer invasion, angiogenesis and metastasis (46-51). The 
cancer cells themselves can also secret IL-8 in an autocrine 
or paracrine manner, such as in breast cancer, gastric cancer, 
colon cancer, cervical cancer, pancreatic cancer and leukemia 
(52). Moreover, in human colon cancer cell lines, constitutive 
expression of IL-8 has been linked to metastatic potential and 
has been suggested to play a role in the development of distant 
metastases. In vivo analysis also showed that IL-8 would be 
a sensitive marker in predicting prognosis and monitoring 
disease progression of the pancreatic cancer patients (52). 
INTERLEUKIN-8 IN HEAD AND NECK CANCER
One of the factors that is known to positively drive metastasis 
is angiogenesis, which has been reported to be associated with 
decreased survival of HNSCC patients (2, 53-55). IL-8, along 
with other factors produced either by normal or malignant 
cells such as VEGF and bFGF has been shown to contribute 
to angiogenesis, tumorigenesis, and metastasis in patients with 
HNSCC (2, 33, 56).
 Serum levels of IL-8 are consistently elevated in patients 
with recurrent or metastatic SCCHN and elevated levels 
may correlate with advanced or aggressive disease (34, 
36, 57); in general, IL-8 production is linked with tumor 
vascularization, metastatic phenotype, tumor growth, and 
overall poor prognosis. A clear switch from cytokine Th1 
to cytokine Th2 in HNSCC patients, low levels of IL-2 and 
increased levels of both IL-2 and IL-12 with the early stages of 
laryngo-pharyngeal cancer were reported (58). Loco-regional 
metastases were correlated with increased levels of IL-8 and 
correlated with increased levels of Th2 cytokines, supporting 
the hypothesis that the ratio between different Th1 and Th2 
cytokines could represent a useful marker for clinical and 
pathological evaluation of cancer patients.
CXCR4 interaction in HNSCC and its secretion is regulated 
by Akt phosphorylation after SDF-1 stimulation (59). These 
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results point out the importance of SDF-1/CXCR4 interaction 
in HNSCC angiogenesis and provides a new targeting therapy 
utility, disrupting SDF-1/CXCR4 interaction combined with 
downstream-induced angiogenic factors in HNSCC would be 
 According to Swenson and colleagues IL-8 and VEGF 
expression is based on interactions between NF-kB, AP-1, and 
induction of AP-1, VEGF, and IL-8 promoter/reporter gene 
activity after 24-hour exposure to cigarette smoke condensate 
(CSC) reporting that tobacco carcinogens up-regulate 
AP-1 activity and AP-1 dependent IL-8 and VEGF gene 
expression in head and neck cancer (60). This up-regulation 
may promote an angiogenic phenotype that favors invasion 
in both premalignant and squamous cancer cells of the head 
activation of both genes, resulting in increased IL-8 and VEGF 
secretion, and these processes could be down-regulated with 
introduction of a dominant negative A-Fos gene. These data 
demonstrate a role for tobacco carcinogen stimulation of pro-
angiogenic cytokines, thus promoting an environment suitable 
for development and metastatic spread of head and neck cancer 
cells. 
INTERLEUKIN-8 IN LARYNGEAL CANCER
The role of IL-8 in the development and progression of LSCC 
has been recently investigated (61). In the last decade, four 
studies focused on the role of IL-8 in LSCC, enrolling a total 
of 214 patients with laryngeal cancer, and 6 patients with 
laryngeal dysplasia (52, 58, 62, 63). IL-8 sample was taken 
by peripheral venous blood, while the types of assays for IL-8 
measurement were ELISA kits. The main results of these 
studies are summarized in Table 1.
 Eyigor et al investigated the relationship between the size 
of tumors, lymph node metastases, stage, differentiation and 
these variables. IL-8 level in patients affected by laryngeal 
cancer ranged from 24.9 pg\ml (52) to 227.15 pg\ml (62). 
Patients with laryngeal dysplasia presented 24.02 pg\ml. IL-8 
cytokine level in controls reached the maximum of 34.33 
(62). These results are in line with two previous studies (33, 
38), although they focused on HNSCC and did not specify 
how many patients had laryngeal cancer compared with other 
sites in head and neck (38). Similarly, Druzgal et al (34) and 
Hathaway et al (36) also demonstrated some elevation in IL-
et al, Gokhale (57) reported that IL-8 was 
not elevated in newly diagnosed patients but in patients with 
recurrence and metastasis of HNSCC. Likewise, Hathaway 
et al (36) also reported that, although IL-8 is not markedly 
increased in cancer patients, it is associated with the tumor 
size.  Serum IL-8 level of patients with LSCC was associated 
overall survival and progression-free survival. Univariate 
and multivariate analyses showed that high IL-6 serum level, 
contrarily to IL-8, was an independent adverse prognostic 
variable for progression free and overall survival (52). 
 Patients with T2 pharyngeal cancer showed that the 
average value of IL-8 was much higher than in patients with 
T2 stage laryngeal cancer (58). In exchange, in T3 group, 
nearly 25% of patients exhibiting high or detectable levels 
of IL-8 had laryngeal cancer. Concerning the Th1/Th2 levels 
levels of IL-8 and IL-10.  Serum level of IL-8 was high in 
patients with loco-regional metastases and was low, although 
noticeable, in patients with reactive nodes. Loco-regional 
consisting of increased levels of IL-8 and IL-10 and a drastic 
immunological balance in these patients with the activation of 
processes. The switch towards a Th2-type response in 
advanced cancer patients and the high levels of IL-8 and 
IL-10 could be responsible of promoting the tumor growth 
through contiguity. The higher level of IL-8 in patients with 
loco-regional metastases demonstrates the importance of this 
cytokine as an indicator of the presence of local metastases, 
potentially contributing to the correct evaluation of patients 
and an adequate therapy selection. 
TNF-receptor-associated-factor (TRAF)-6 mRNA expression 
and IL-8 secretion when stimulated with phytohaemagglutinin 
(PHA) in patients with laryngeal carcinomas (63). These 
authors found that patients with carcinomas characterized 
by the highest TRAF6 mRNA expression had higher IL-8 
concentration. They also noted the positive relationship 
between toll-like receptor-4 (TLR-4) mRNA status and IL-8 
concentration, but this association had borderline statistical 
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Table 1
studies included 214 patients with laryngeal cancer and 6 patients with laryngeal dysplasia.
Reference № of patients
Sample taken; 
types of 
assays for IL-8 
measurement





Mean ± SE 
(pg/ml)
Comments
Eyigor et al 
(2014) (62)
17 patients with 







Levels of IL-8: 227.15 ± 81.19 in 
patients with L SCC (p<0.05);
24.02 ± 11.57 in patients with 
laryngeal dysplasia;
Levels of IL-8: 
34.33 ± 12.60
No significant difference between 
tumor size, lymph node metastases, 
stage, differentiation and cytokine 
levels
Hao et al 
(2013) (52)
92 patients with 
primary diagnosis 
of LSCC;
50 age and 
gender matched 
healthy blood 
donors with no 
previous cancer 





24.9 [3.6–56.0], (p < 0.0001) 14.5 [2.3–42.6], 
(p < 0.0001)
Serum levels of IL-8 were only 
associated with lymph node 
metastasis (p=0.01) and T 
classification (p=0.011)
Bleotu et al 
(2013) (58)
50 patients with 
laryngeal (n = 41) 
or pharyngeal  




123.47 ± 282.66 0.0 ± 0.0 Loco-regional metastases were 
correlated with increased levels of 
IL-8 and IL-10 and drastic decrease 
of IFNɤ. 
Starska et al 
(2012) (63)
55 patients with 
LSCC. The control 







119.69 ± 29.95 ng/mL; 
proinflammatory cytokine 
production following mitogenic 
stimulation was 231.56 ± 29.95 ng/
mL. The secretion pattern of  
carcinomas with the invasion  
of cartilage was 97.4 ± 18.81 ng/mL, 
as well as 243.5 ± 81.77 ng/
mL with mitogenic stimulation. 
Proinflammatory cytokine 
production of tumors characterized 
by mode of invasion with no 
distinct borderlines was 139.5 ± 
53.33 ng/mL, as well as 266.9 ± 
84.45 ng/mL following mitogenic 
stimulation, respectively. In 
carcinomas with 14-17 points TFG 
was 122.5 ± 38.24 ng/mL, as well as 
270.5 ± 56.17 ng/mL in experiments 
with mitogenic stimulation.
In all cases of LSCC the evaluation 
of proinflammatory cytokine 
expression, disclosed the presence 
of significant positive relationships 
between TRAF6 mRNA expression 
and IL-8. secretion when 
stimulated with PHA (r=0.83, 
p=0.009). Patients with carcinomas 
characterized by the highest 
TRAF6 mRNA expression, were 
found to demonstrate higher IL-8 
concentration. It was also noted 
a positive relationship between 
TLR4 mRNA status and IL-8 
concentration, but this association 
had borderline statistical 
significance (r=0.67, p=0.06).
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more invasive laryngeal carcinomas characterized by a higher 
disseminated tumor invasion (with no distinct borderlines 
of the tumor front or with diffuse growth), demonstrated a 
lower mRNA expression of each TLR pathway molecule in 
immunocompetent cells. Moreover, it was observed that the 
more advanced histological laryngeal neoplasm (with higher 
scores according to TFG total points), the lower TLR4 and 
TRAF6 mRNA expression in peripheral blood mononuclear 
reporting that the TLR pathway molecules are the key 
mediators of immune mechanisms, which result in activation 
TLR signaling molecules, connected with a less disseminated 
evidence of unsuppressed anti-tumor immunological response 
in these types of neoplasms. Moreover, these results suggest 
the presence of alterations in immunological activity and 
circulating immunocompetent cell, which lead to inhibition 
of tumor progression in advanced laryngeal cancer. Based on 
TLR signaling molecules might be good potential biomarkers 
of tumor behavior in LSCC as they could potentially determine 
the aggressiveness of laryngeal cancer acting through 
regulatory mechanisms of interleukin production. 
CONCLUSIONS
The mechanisms of cancer origin, invasion, and metastasis 
in head and neck cancer, especially in LSCC. Tumor, lymph 
the estimation of tumor aggressiveness; moreover, different 
conclusions may result from a heterogeneous group of 
investigated HNSCC cancers in different locations such as 
oral cancers, laryngopharyngeal carcinomas, nasal cavities 
and paranasal sinuses tumors (1, 4, 22-24, 65-68).. Biomarkers 
such as IL-8 deserve further investigation as they could have a 
role as a screening test for head and neck cancer. To date, there 
is little and still contrasting evidence on the role of IL-8 in 
LSCC; however, preliminary data available in the literature are 
encouraging and could suggest a role for IL-8 as a support of 
the clinical decisions for appropriate therapy and postoperative 
care in individual patients affected by laryngeal cancer.
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